Understanding the Need for Better Post-PCI Risk Prediction Dual antiplatelet therapy (DAPT), typically aspirin plus a P2Y12 receptor antagonist, is standard after percutaneous coronary intervention (PCI) with drug-eluting stents. While this approach reduces stent thrombosis and major adverse cardiac events (MACE), individual responses to antiplatelet drugs vary widely. High residual platelet reactivity (HRPR) after clopidogrel…